Risk Management And The Combination Product Testing Strategy

By D. Bantz

Understanding combination product risks at the interfaces is critical. Components are often sourced at opposite ends of the globe and are proven to be robust due to investments in research, development and testing. It is essential to have an equal and complete understanding of all components where they come together at the interfaces where the risks are hidden. Understanding the essential performance of the combination product at all stages is a win-win for the patient and all stakeholders within the supply chain.

access the Poster!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Biosimilar Development? Subscribe today.

Subscribe to Biosimilar Development X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Biosimilar Development

West Pharmaceutical Services, Inc.